Maixin Pathology Diagnostic Center Obtains Medical Institution Practice License!
On May 11, 2017, with the official approval of the Health and Family Planning Commission, the establishment of Fuzhou Maxin Pathology Diagnostic Center was approved, and the Medical Institution Practice License was issued. It is the first private professional pathology diagnostic center with the largest investment and scale since the National Health and Family Planning Commission issued the Notice on Printing the Basic Standards and Management Specifications for Pathology Diagnostic Centers (Trial) (Document No. 65 [2016]) on December 21, 2016, and also the first pathology diagnostic center in Fujian. This project is a key project under the Fujian Provincial Government’s “Five Batches” initiative.
Maxin Pathology Diagnostic Center has a registered capital of 50 million yuan and is a wholly-owned subsidiary of Fuzhou Maxin Biotechnology Development Co., Ltd. The establishment of this center marks Maxin’s strategic layout to integrate 24 years of expert resources, market resources, and product resources, transitioning from solely researching, producing, and selling immunohistochemistry reagents to comprehensively providing overall solutions for pathology departments.
Maxin Pathology Diagnostic Center is based in Fujian, radiates to the West Coast Economic Zone, and serves the whole country. It fully carries out cytopathology, histopathology, molecular pathology testing and diagnostic services, as well as precision medicine companion diagnostics and research services. Relying on authoritative domestic hospitals and authoritative medical institutions and experts from the United States, Japan, Hong Kong, Taiwan, and other countries and regions, it establishes an international remote consultation platform and an international medical service system.
The emergence of more and more third-party testing centers, pathology diagnostic centers, and imaging centers plays a positive role in achieving hierarchical diagnosis and treatment, sinking medical resources, meeting the needs of primary medical services, and solving medical difficulties. However, severe homogenization of service items and one-sided pursuit of being large and comprehensive will lead to new waste of medical resources and competitive risks. Pathology diagnostic centers will fully leverage the brand advantages, cost advantages, and channel advantages of enterprises, adopt a mechanism of cooperation, sharing, integration, and win-win, and establish mutually beneficial development platforms with more enterprises, medical institutions, third-party medical testing centers, medical consortia, and pathology physician groups.